PMC:7195088 / 19212-19468 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"666","span":{"begin":118,"end":126},"obj":"Species"},{"id":"774","span":{"begin":12,"end":30},"obj":"Chemical"},{"id":"775","span":{"begin":35,"end":54},"obj":"Chemical"},{"id":"776","span":{"begin":83,"end":93},"obj":"Chemical"},{"id":"928","span":{"begin":132,"end":140},"obj":"Disease"}],"attributes":[{"id":"A666","pred":"tao:has_database_id","subj":"666","obj":"Tax:9606"},{"id":"A774","pred":"tao:has_database_id","subj":"774","obj":"MESH:D006886"},{"id":"A775","pred":"tao:has_database_id","subj":"775","obj":"MESH:C558899"},{"id":"A776","pred":"tao:has_database_id","subj":"776","obj":"MESH:C000606551"},{"id":"A928","pred":"tao:has_database_id","subj":"928","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"tonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":251,"end":256},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"tonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T95","span":{"begin":132,"end":140},"obj":"Disease"}],"attributes":[{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"tonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T97","span":{"begin":233,"end":236},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"}],"text":"tonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T180","span":{"begin":12,"end":30},"obj":"Chemical"},{"id":"T181","span":{"begin":35,"end":54},"obj":"Chemical"},{"id":"T182","span":{"begin":35,"end":44},"obj":"Chemical"},{"id":"T183","span":{"begin":45,"end":54},"obj":"Chemical"},{"id":"T184","span":{"begin":60,"end":70},"obj":"Chemical"},{"id":"T185","span":{"begin":71,"end":75},"obj":"Chemical"},{"id":"T186","span":{"begin":83,"end":93},"obj":"Chemical"}],"attributes":[{"id":"A180","pred":"chebi_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A181","pred":"chebi_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A182","pred":"chebi_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A183","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A184","pred":"chebi_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A185","pred":"chebi_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A186","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"tonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale"}

{"project":"LitCovid-sentences","denotations":[{"id":"T133","span":{"begin":142,"end":195},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"tonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale"}